Trial Profile
A single-arm, prospective Clinical Study of apatinib combined with SOX protocol for first-line treatment of advanced gastric cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 Aug 2018 New trial record